 Drug Combinations
"Drug Combinations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
| Descriptor ID |
D004338
|
| MeSH Number(s) |
D26.310
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Combinations".
Below are MeSH descriptors whose meaning is more specific than "Drug Combinations".
- Drug Combinations
- Adapalene, Benzoyl Peroxide Drug Combination
- Albuterol, Ipratropium Drug Combination
- Aminophylline
- Amlodipine Besylate, Olmesartan Medoxomil Drug Combination
- Amlodipine, Valsartan Drug Combination
- Aspirin, Dipyridamole Drug Combination
- Biphasic Insulins
- Brimonidine Tartrate, Timolol Maleate Drug Combination
- Budesonide, Formoterol Fumarate Drug Combination
- Buprenorphine, Naloxone Drug Combination
- Contraceptives, Oral, Combined
- Dimenhydrinate
- Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Emtricitabine, Rilpivirine, Tenofovir Drug Combination
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Ezetimibe, Simvastatin Drug Combination
- Fluticasone-Salmeterol Drug Combination
- Mometasone Furoate, Formoterol Fumarate Drug Combination
- Multi-Ingredient Cold, Flu, and Allergy Medications
- Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
- Trimethoprim, Sulfamethoxazole Drug Combination
This graph shows the total number of publications written about "Drug Combinations" by people in this website by year, and whether "Drug Combinations" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 | | 1996 | 0 | 2 | 2 | | 1997 | 0 | 3 | 3 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 4 | 4 | | 2003 | 0 | 5 | 5 | | 2004 | 0 | 5 | 5 | | 2005 | 0 | 5 | 5 | | 2006 | 0 | 6 | 6 | | 2007 | 0 | 3 | 3 | | 2008 | 0 | 7 | 7 | | 2009 | 0 | 6 | 6 | | 2010 | 0 | 6 | 6 | | 2011 | 1 | 11 | 12 | | 2012 | 0 | 6 | 6 | | 2013 | 0 | 8 | 8 | | 2014 | 1 | 8 | 9 | | 2015 | 0 | 5 | 5 | | 2016 | 0 | 13 | 13 | | 2017 | 0 | 13 | 13 | | 2018 | 0 | 12 | 12 | | 2019 | 0 | 13 | 13 | | 2020 | 0 | 12 | 12 | | 2021 | 0 | 21 | 21 | | 2022 | 0 | 12 | 12 | | 2023 | 0 | 7 | 7 | | 2024 | 3 | 9 | 12 | | 2025 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Combinations" by people in Profiles.
-
Chappell CA, Kiser JJ, Brooks KM, Randolph R, Macio IS, Meyn LA, MaWhinney S, Rick AM, Muniz GB, Kwon KM, Letterio C, Naik S, Kreter B, Bunge KE, Krans EE, Hillier SL. Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clin Infect Dis. 2025 Apr 30; 80(4):744-751.
-
Fireizen Y, Ahmed M, Vigers T, Akong K, Ryu J, Hahn A, Fanous H, Koumbourlis A, Tirakitsoontorn P, Arrieta A, Burgener EB, Koff J, Cogen JD, Bouzek DC, Hanley E, Keck A, Stout D, Bradley J, Sagel SD. Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis. Pediatr Pulmonol. 2025 Mar; 60(3):e71019.
-
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025 Mar; 13(3):256-271.
-
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med. 2025 Mar; 13(3):244-255.
-
Metcalf A, Martiniano SL, Sagel SD, Zaretsky MV, Zemanick ET, Hoppe JE. Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis. J Cyst Fibros. 2025 May; 24(3):466-468.
-
Mayer-Hamblett N, Gifford AH, Kloster M, Russell R, Braun AT, Gibson RL, Hoppe JE, Jain R, Linnemann RW, Liou TG, Lysinger J, Milla C, Riekert KA, Sawicki GS, Young J, Nichols D. Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. Ann Am Thorac Soc. 2024 Nov; 21(11):1507-1515.
-
Riddler SA, Kelly CW, Hoesley CJ, Ho KS, Piper JM, Edick S, Heard F, Doncel GF, Johnson S, Anderson PL, Brand RM, Kunjara Na Ayudhya RP, Bauermeister JA, Hillier SL, Hendrix CW. A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention. J Infect Dis. 2024 Sep 23; 230(3):696-705.
-
Bose-Brill S, Hirabayashi K, Schwimmer E, Pajor NM, Rao S, Mejias A, Jhaveri R, Forrest CB, Bailey LC, Christakis DA, Thacker D, Hanley PC, Patel PB, Cogen JD, Block JP, Prahalad P, Lorman V, Lee GM. Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic. Hosp Pediatr. 2024 08 01; 14(8):e341-e348.
-
Kim U, Perzia B, Kulkarni P, Rajiniganth M, Sundar B, Robin AL, Garg Shukla A, Maeng MM. COVID-19-associated rhino-orbito-cerebral mucormycosis: a single center prospective study of 264 patients. Orbit. 2025 Feb; 44(1):24-33.
-
Van Hove JLK, Friederich MW, Hock DH, Stroud DA, Caruana NJ, Christians U, Schniedewind B, Michel CR, Reisdorph R, Lopez Gonzalez EDJ, Brenner C, Donovan TE, Lee JC, Chatfield KC, Larson AA, Baker PR, McCandless SE, Moore Burk MF. ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis. Mitochondrion. 2024 Sep; 78:101905.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|